In this report, “Stereotaxis”, the “Company”, “Registrant”, “we”, “us”, and “our” refer to Stereotaxis, Inc. and its wholly owned subsidiaries. Epoch®, Niobe®, Odyssey®, Odyssey Cinema™, Vdrive®, Vdrive Duo™, V-CAS™, V-Loop™, V-Sono™, V-CAS Deflect™, QuikCAS™, and Cardiodrive® are trademarks of Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners.
- our business strategy; - our value proposition; - our ability to fund operations; - our ability to convert backlog to revenue; - the ability of physicians to perform certain medical procedures with our products safely, effectively and efficiently; - the adoption of our products by hospitals and physicians; - the market opportunity for our products, including expected demand for our products; - the timing and prospects for regulatory approval of our additional disposable interventional devices; - the success of our business partnerships and strategic relationships; - our estimates regarding our capital requirements; - our plans for hiring additional personnel; and - any of our other plans, objectives, expectations and intentions contained in this annual report that are not historical facts.
We design, manufacture and market robotic systems and instruments for use primarily by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias. We offer our proprietary Epoch Solution, an advanced remote robotic navigation system, for use in a hospital's interventional surgical suite, or “interventional lab”. We believe the Epoch Solution revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional procedures.